Literature DB >> 20951441

Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis.

Klaus-Peter Wandinger1, Sandra Saschenbrecker, Winfried Stoecker, Josep Dalmau.   

Abstract

Anti-NMDA-receptor encephalitis is a severe, treatable and potentially reversible disorder presenting with memory deficits, psychiatric symptoms and seizures. Initially described in young patients with ovarian teratoma, the disease is meanwhile increasingly recognized also in women without tumours, in men and in children. The presence of anti-glutamate receptor (type NMDA) autoantibodies in serum or cerebrospinal fluid is specific for this novel and widely underdiagnosed disorder. Early recognition is crucial since prognosis largely depends on adequate immunotherapy and, in paraneoplastic cases, complete tumour removal. Indirect immunofluorescence using NMDA-type glutamate receptors recombinantly expressed in human cells is a highly competent method for diagnosing anti-NMDA-receptor encephalitis.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951441     DOI: 10.1016/j.jneuroim.2010.09.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  74 in total

1.  Cognitive deficits following anti-NMDA receptor encephalitis.

Authors:  Carsten Finke; Ute A Kopp; Harald Prüss; Josep Dalmau; Klaus-Peter Wandinger; Christoph J Ploner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-09-20       Impact factor: 10.154

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Spontaneous recovery from anti-NMDAR encephalitis.

Authors:  Amelia Evoli; Pietro Spinelli; Giovanni Frisullo; Paolo E Alboini; Serenella Servidei; Camillo Marra
Journal:  J Neurol       Date:  2012-03-03       Impact factor: 4.849

4.  Autoimmune limbic encephalitis presenting as relapsing psychosis.

Authors:  Sarah A Hopkins; Kuven K Moodley; Dennis Chan
Journal:  BMJ Case Rep       Date:  2013-08-30

5.  Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.

Authors:  C Hammer; B Stepniak; A Schneider; S Papiol; M Tantra; M Begemann; A-L Sirén; L A Pardo; S Sperling; S Mohd Jofrry; A Gurvich; N Jensen; K Ostmeier; F Lühder; C Probst; H Martens; M Gillis; G Saher; F Assogna; G Spalletta; W Stöcker; T F Schulz; K-A Nave; H Ehrenreich
Journal:  Mol Psychiatry       Date:  2013-09-03       Impact factor: 15.992

6.  IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment.

Authors:  H Prüss; M Höltje; N Maier; A Gomez; R Buchert; L Harms; G Ahnert-Hilger; D Schmitz; C Terborg; U Kopp; C Klingbeil; C Probst; S Kohler; J M Schwab; W Stoecker; J Dalmau; K P Wandinger
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

7.  Young girl with psychosis, cognitive failure and seizures.

Authors:  Imer Önder Slettedal; Hilde Margrete Dahl; Inger Sandvig; Josep Dalmau; Petter Strømme
Journal:  Tidsskr Nor Laegeforen       Date:  2012-10-02

8.  [Therapeutic apheresis for autoimmune encephalitis: a nationwide data collection].

Authors:  S Ehrlich; C M Fassbender; C Blaes; C Finke; A Günther; L Harms; F Hoffmann; K Jahner; R Klingel; A Kraft; T Lempert; M Tesch; J Thomsen; H Topka; J Jochim; C Veauthier; W Köhler
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

9.  Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor.

Authors:  Makoto Hara; Eugenia Martinez-Hernandez; Helena Ariño; Thais Armangué; Marianna Spatola; Mar Petit-Pedrol; Albert Saiz; Myrna R Rosenfeld; Francesc Graus; Josep Dalmau
Journal:  Neurology       Date:  2018-03-16       Impact factor: 9.910

10.  Anti-NMDAR encephalitis: a new, severe and challenging enduring entity.

Authors:  Emma H C W van de Riet; Maite M Esseveld; Leen Cuypers; Jan N M Schieveld
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-12-19       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.